ICD-10 code C25.7: Malignant neoplasm of other parts of pancreas



Key Takeaways

C25.7 is a billable ICD-10-CM code covering malignant neoplasm of other parts of pancreas, including the neck and uncinate process

C25.7 groups into MS-DRG 435, 436, and 437 under MS-DRG v43.0, with reimbursement varying by MCC and CC presence

Never default to C25.9 (unspecified) when operative or pathology reports identify the neck or uncinate process as the tumor site

Pabau’s claims management software helps oncology and gastroenterology billing teams track C25.7 claims and reduce pancreatic cancer coding errors

ICD-10 Code C25.7: definition and clinical description

ICD-10 Code C25.7 is the billable ICD-10-CM diagnosis code for malignant neoplasm of other parts of pancreas, including the neck of the pancreas. It is valid for HIPAA-covered transactions beginning October 1, 2024, per ICD List. The code sits within chapter C00-D49 (Neoplasms) of the ICD-10-CM tabular list, under category C25 (Malignant neoplasm of pancreas).

C25.7 captures pancreatic tumors located at sites not individually represented by the other C25 subcategories. This article covers the anatomical scope, code hierarchy, MS-DRG groupings, HCC mapping, documentation requirements, and the most common coding pitfalls for C25.7.

Applicable to inclusions

The ICD-10-CM tabular list includes one official “Applicable To” note under C25.7:

• Malignant neoplasm of neck of pancreas

The neck is the short segment connecting the head and body of the pancreas, situated anterior to the superior mesenteric vessels. Clinicians and pathologists sometimes also document tumors of the uncinate process here when the site does not clearly belong to the head (C25.0). Coders should verify anatomical language in the operative or pathology report before assigning C25.7 to uncinate process tumors; when ambiguous, query the physician.

C25 code family: where ICD-10 Code C25.7 fits

Getting C25.7 right means knowing the full C25 family. Each subcategory maps to a distinct anatomical segment, so documentation specificity drives code selection.

C25.9 is a last resort. When clinical documentation identifies any of the specific sites above, use the most precise code. Defaulting to C25.9 on a chart that documents “neck of pancreas” creates an audit risk and may reduce HCC capture accuracy.

C25.7 vs C25.9: the unspecified coding trap

C25.9 is appropriate only when the treating physician has not documented a specific site and a physician query would be clinically unreasonable. If radiology, pathology, or operative notes name the neck, code C25.7. Using ICD-10 documentation guidelines to support site specificity protects reimbursement and risk-adjustment accuracy. According to the CMS ICD-10 coding guidance, coders must assign the code that reflects the highest level of specificity supported by the documentation.

C25.7 vs C25.8: overlapping sites

C25.8 applies when a tumor explicitly spans two or more contiguous, named sites in the C25 family. A tumor described as involving “the neck and body” warrants C25.8, not C25.7. When documentation is ambiguous, coders should query the treating physician before assigning either code.

MS-DRG groupings for ICD-10 Code C25.7

C25.7 groups into three MS-DRGs under version 43.0, with reimbursement determined by the presence or absence of complications and comorbidities (CC) and major complications and comorbidities (MCC).

Documenting secondary diagnoses that qualify as MCCs (such as sepsis, respiratory failure, or acute renal failure) shifts the encounter from DRG 437 to DRG 435, with a substantially higher geometric mean length of stay and reimbursement weight. Accurate secondary-diagnosis coding on these encounters has direct financial implications.

HCC mapping and risk adjustment for pancreatic cancer codes

Under the CMS Hierarchical Condition Category (HCC) model, pancreatic malignancies carry significant risk-adjustment weight. C25.7 maps to HCC categories associated with severe cancers, which drive higher Risk Adjustment Factor (RAF) scores for Medicare Advantage and other risk-adjusted payment models.

According to CMS risk-adjustment education materials, pancreatic cancer codes including C25.7 fall under HCC 8 (Metastatic Cancer and Acute Leukemia) or HCC 9 (Lung and Other Severe Cancers), depending on whether metastatic disease is also documented. The distinction matters: HCC 8 carries a higher RAF coefficient than HCC 9, reflecting the greater resource utilization and cost burden of metastatic disease.

• HCC 8 applies when metastatic involvement is also coded (e.g., C78.89 for secondary malignant neoplasm of other digestive organs alongside C25.7)
• HCC 9 applies when C25.7 is coded without a documented metastatic secondary
• Both HCC 8 and HCC 9 require annual recapture: if not coded in the current measurement year, the RAF score does not reflect the patient’s cancer burden

Use the HCC ICD-10 Crosswalk to verify the current-year HCC mapping for C25.7 against the applicable CMS model version, as HCC assignments can shift between model years.

Practices using claims management software with integrated diagnosis tracking can set alerts to flag C25.x encounters where metastatic codes may be missing, reducing the risk of undercoded HCC categories on RAF-sensitive patient panels.

Documentation requirements for accurate C25.7 coding

Three source documents determine whether C25.7 is supportable: the operative report, the pathology report, and the treating physician’s clinical notes. Each has a different level of authority depending on the clinical setting.

What the record must say

• Anatomical specificity: the record must explicitly name the neck of the pancreas (or another site captured under C25.7) as the primary tumor location
• Malignancy confirmation: documentation must confirm a malignant, not benign or uncertain, behavior; cystic lesions with uncertain behavior may require a different code entirely
• Histological type: adenocarcinoma, neuroendocrine carcinoma, and other histologies map differently; the ICD-10-CM code captures site, not histology, but the histology documentation supports medical necessity for staging and treatment coding
• Physician attestation: for inpatient coding, the final diagnosis on the discharge summary governs code selection; radiology and pathology findings support but do not replace physician documentation

Maintaining HIPAA-compliant documentation practices means retaining the full clinical record to support ICD-10-CM code assignment during payer audits. Patient record management systems that timestamp physician entries and link pathology attachments directly to the encounter note reduce audit exposure substantially.

Outpatient vs inpatient documentation rules

Outpatient encounters follow the ICD-10-CM Official Guidelines Section IV, which prohibit coding a confirmed malignancy from radiology findings alone without physician documentation of the diagnosis. Inpatient encounters follow Section II, where the coder may reference pathology and radiology if the attending physician has not contradicted those findings in the discharge summary. For C25.7, this means outpatient coders in oncology or gastroenterology practices should obtain a written diagnosis from the treating physician before assigning the code, even when the pathology is unambiguous.

Streamlining this process through digital clinical forms that capture physician sign-off at the point of care reduces the documentation lag that leads to delayed coding and denied claims.

Reduce pancreatic cancer claim denials with Pabau

Pabau's claims management tools help oncology and gastroenterology billing teams track ICD-10 codes accurately, flag missing secondary diagnoses, and stay audit-ready across every encounter.

Book a demo

Coding pitfalls and audit risks for C25.7

Pancreatic cancer coding attracts payer scrutiny because of its high reimbursement weight. These are the four patterns most likely to trigger a denial or an overpayment recoupment.

Pitfall 1: defaulting to C25.9 when site is documented

The most common error. When the pathology report reads “primary adenocarcinoma of the neck of the pancreas,” C25.9 is incorrect and C25.7 is the required code. Payers running clinical data analysis tools can identify high C25.9 rates against a backdrop of surgical and pathology claims that imply site specificity, flagging practices for coding accuracy reviews. Consistent use of ICD-10-CM code selection protocols tied to documentation review reduces this risk.

Pitfall 2: neuroendocrine carcinoma coding

Coding neuroendocrine carcinoma of the pancreas is contested among coders. C25.4 (malignant neoplasm of endocrine pancreas) covers islet cell tumors and neuroendocrine tumors arising from endocrine cells. C25.7 applies when the neuroendocrine tumor’s anatomical site is the neck and the pathology does not specify an islet cell origin. Because this distinction is genuinely uncertain in some cases, the AHA Coding Clinic is the authoritative reference. Until official guidance is published, the safest approach is to query the treating physician when pathology reports describe a neuroendocrine carcinoma of the neck of the pancreas without further histological detail.

Pitfall 3: missing secondary malignancy codes

Pancreatic cancer frequently presents with hepatic or peritoneal metastases at diagnosis. When metastatic disease is documented, secondary malignancy codes (e.g., C78.7 for secondary malignant neoplasm of liver) must be coded alongside C25.7. Omitting them understates disease severity, reduces HCC capture, and misrepresents the clinical complexity that drives DRG assignment. EHR integration for billing workflows that flag metastasis-related diagnosis codes at encounter creation helps prevent this omission.

Pitfall 4: ICD-9-CM confusion on legacy records

For practices handling pre-October 2015 records or cross-walking for research purposes, the predecessor ICD-9-CM code for C25.7 was 157.8 (Malignant neoplasm of other specified sites of pancreas). This crosswalk is one-to-one but should be verified for any legacy billing or retrospective analysis. The AAPC Codify ICD-10-CM lookup includes ICD-9 conversion tools for this purpose.

Clinical context: pancreatic cancer at the neck

The neck of the pancreas is a surgically significant location. Its proximity to the superior mesenteric artery and portal vein means tumors here are frequently borderline-resectable or unresectable at presentation, according to the National Library of Medicine’s clinical terminology resources and published oncology literature.

Clinically, pancreatic adenocarcinoma is the predominant histology across all C25.x codes. Neuroendocrine tumors are less common and behave differently: they tend to be slower-growing and more amenable to surgical resection. The distinction matters for coding because histology drives the secondary procedure and treatment codes that accompany C25.7 on a claim.

Practices managing oncology patients benefit from a structured automated workflow that routes new malignancy encounters through a coding review checkpoint before submission. This is particularly relevant for multi-specialty practices where a gastroenterologist initiates the diagnosis but surgical and oncology teams generate subsequent claims.

The WHO’s ICD-10 browser classifies C25.7 under Malignant neoplasms of digestive organs, providing the international coding framework that aligns with the U.S. ICD-10-CM adaptation maintained by the CDC/NCHS ICD-10-CM web tool.

Conclusion

Defaulting to C25.9 on a pancreatic cancer chart that clearly documents the neck as the tumor site is one of the most common and most costly coding errors in oncology billing. C25.7 is the correct, specific, billable code for that scenario, and using it accurately captures HCC risk scores, supports the right MS-DRG assignment, and withstands payer audits.

Pabau’s claims management software gives oncology and gastroenterology billing teams the tools to track secondary diagnosis completeness, flag under-coded malignancy encounters, and maintain the documentation audit trail that supports C25.x code accuracy. Book a demo to see how Pabau handles complex oncology billing workflows.

Continue your research

Need a structured framework for clinical documentation compliance? HIPAA compliance for medical offices covers the documentation requirements that support accurate diagnosis coding and audit defense.

Looking for guidance on managing intraparenchymal and other complex ICD-10 diagnoses? Intraparenchymal hemorrhage ICD-10 codes walks through another high-complexity diagnostic coding scenario with documentation and sequencing guidance.

Want to reduce billing errors across your oncology or gastroenterology practice? Practice management software explains how integrated platforms reduce claim errors and support complete secondary-diagnosis coding at scale.

Frequently Asked Questions